Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

Hannah Kibuuka(Makerere University Walter Reed Project), Julie E. Ledgerwood(Vaccine Research Institute of San Diego), Nancy J. Sullivan(National Institute of Allergy and Infectious Diseases), Sandra Sitar(National Institutes of Health), Pamela Costner(National Institutes of Health), Richard A. Koup(Aaron Diamond AIDS Research Center), Barney S. Graham(National Institutes of Health), Deline Glover, Zonghui Hu(National Institutes of Health), Nelson L. Michael(Walter Reed Army Institute of Research), Mary E. Enama(National Institutes of Health), Leigh Anne Eller, Gary J. Nabel(National Institutes of Health), Robert T. Bailer(National Institutes of Health), John R. Mascola(National Institute of Allergy and Infectious Diseases), Merlin L. Robb(University of Maryland, Baltimore), Allan Tindikahwa(Makerere University Walter Reed Project), Arthur Sekiziyivu(Makerere University Walter Reed Project), Gyan Joshi(National Institutes of Health), Mario Roederer(National Institutes of Health), Daphne A. Stanley(National Institutes of Health), Meghan Kunchai(Emmes (United States)), Monica Millard(Walter Reed Army Institute of Research), Nina M. Berkowitz(National Institutes of Health)
The Lancet
December 22, 2014
Cited by 126


Related Papers